On January 1, 2021, Rose Apothecary, Inc. granted stock options to officers and key employees for the purchase of 30,000 shares of the company's $10 par common stock at $20 per share. The options were exercisable within an 8-year period beginning January 1, 2024, by grantees still in the employ of the company, and expiring December 31, 2028. The service period for this award is 3 years. Assume that the fair value option-pricing model determines total compensation expense to be $450,000.

On March 31, 2024, 12,000 options were exercised when the market price of the common stock was $45 per share.

Instructions

Prepare journal entries to record issuance of the stock options, exercise of the stock options, and charges to compensation expense, for the years ended December 31, 2021, 2022, 2023, and 2024.